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Abstract
Background: Despite recent increased clinical trials activity, no regimen has proved able to replace the standard
6-month regimen for drug-sensitive tuberculosis. Understanding the relationship between microbiological markers
measured during treatment and long-term clinical outcomes is critical to evaluate their usefulness for decision-
making for both individual patient care and for advancing novel regimens into time-consuming and expensive
pivotal phase III trials.
Methods: Using data from the randomized controlled phase III trial REMoxTB, we evaluated sputum-based markers of
speed of clearance of bacilli: time to smear negative status; time to culture negative status on LJ or in MGIT; daily rate
of change of log10(TTP) to day 56; and smear or culture results at weeks 6, 8 or 12; as individual- and trial-level
surrogate endpoints for long-term clinical outcome.
Results: Time to culture negative status on LJ or in MGIT, time to smear negative status and daily rate of change in
log10(TTP) were each independent predictors of clinical outcome, adjusted for treatment (p <0.001). However,
discrimination between low and high risk patients, as measured by the c-statistic, was modest and not much higher
than the reference model adjusted for BMI, history of smoking, HIV status, cavitation, gender and MGIT TTP.
Conclusions: Culture conversion during treatment for tuberculosis, however measured, has only a limited role in
decision-making for advancing regimens into phase III trials or in predicting the outcome of treatment for individual
patients. REMoxTB ClinicalTrials.gov number: NCT00864383.
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Background
The recent failure to reduce the duration of tuberculosis
(TB) treatment from 6 to 4 months using fluoroquino-
lones in three major phase III trials [1–3] should prompt
a review of how decisions are made to move novel regi-
mens to pivotal phase III trials in the drug development
pathway.
TB was declared a global emergency by the World
Health Organization (WHO) as far back as 2003, with
9.0 million new cases and 1.5 million deaths worldwide
from TB in 2013 [4]. It is widely recognized that new
treatment regimens are urgently needed to end the TB
epidemic [5]. New drugs and regimens are in the pipe-
line for drug-sensitive TB and multi-drug-resistant TB
(MDR-TB) with a number of phase III trials for novel
regimens starting over the next few years. Although
there is a modest association between late culture con-
version and poor outcomes for individual patients on
standard treatment [6, 7], this relationship is unknown
for other regimens. A better understanding of how the
available microbiological markers measured during treat-
ment relate to long-term clinical outcomes will enable
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improved decision-making for both individual patient
care and moving regimens into time-consuming expen-
sive pivotal phase III trials.
A surrogate endpoint is defined as “a laboratory meas-
urement or a physical sign used as a substitute for a
clinically meaningful endpoint. … Changes induced by a
therapy on a surrogate endpoint are expected to reflect
changes in a clinically meaningful endpoint” [8]. Al-
though not usually a perfect surrogate, the primary effi-
cacy endpoint of a phase II trial is chosen so that
differences between interventions in the endpoint are
expected to reflect differences between interventions in
a more clinically meaningful phase III endpoint, irre-
spective of the interventions being compared. This is
often described as trial-level surrogacy in contrast to
individual-level surrogacy, which relates to the degree to
which the results of an early outcome are predictive of
the long-term clinical outcome in individual patients
undergoing the same treatment.
Culture positivity on LJ solid media at either 2 or
3 months is not an acceptable surrogate endpoint for
long-term clinical outcome [9–11], although it is the
only marker that has undergone rigorous evaluation.
The inherent lower statistical power of a dichotomous
compared to a continuous endpoint means TB phase II
trials are now rarely designed with these endpoints.
Rather, time to culture conversion [12] or the slope
of quantitative cultures on solid or liquid media over
time [13, 14] are more commonly used as they permit
smaller trials and are thought to be more reliable for
comparing regimens by capturing an element of time
on treatment. As an example, bedaquiline received accel-
erated approval by the US Food and Drug Administration
(FDA) based on time to culture conversion as the
primary efficacy measure [15]. Despite this, the place
of these markers in regimen development has not yet
been formally evaluated, mainly due to the paucity of
data collected in the majority of previous TB phase
III trials [16]. The REMoxTB trial was designed with
weekly cultures during the first 8 weeks and monthly
cultures to the end of treatment to allow for the
evaluation of the role of various measures of bacil-
lary clearance in response to treatment as individual-
level and trial-level surrogates for long-term clinical
outcome.
Methods
Eligible patients in the REMoxTB trial were randomized
to one of three daily regimens: a control regimen con-
sisting of isoniazid and rifampicin for 6 months supple-
mented by pyrazinamide and ethambutol for the first
2 months; 4 months of rifampicin, moxifloxacin and iso-
niazid supplemented by pyrazinamide for the first
2 months (isoniazid arm); and 4 months of rifampicin
and moxifloxacin supplemented by pyrazinamide and
ethambutol for the first 2 months (ethambutol arm) as
reported previously [1].
Sputum samples were taken for smear and culture
weekly to 8 weeks during treatment, monthly thereafter
to 6 months and 3-monthly thereafter to 18 months
from randomization. All cultures were performed in par-
allel using LJ and MGIT and so time to culture negative
status could be measured separately. Sputum was decon-
taminated with acetylcysteine–sodium hydroxide prior
to culture and mycobacterial speciation was performed
using the AccuProbe assay (Gen-Probe, San Diego, CA,
USA). The REMoxTB laboratory and quality manuals
are available on request.
Markers of speed of clearance of bacilli were deter-
mined as follows: 1) time to culture negative status on
LJ or in MGIT; 2) rate of change of time to positivity on
MGIT culture (TTP) over time; 3) time to smear
negative status; 4) culture negative on LJ or in MGIT at
6, 8 or 12 weeks after randomization; and 5) smear nega-
tive at 6, 8 or 12 weeks after randomization. Time to
culture negative status was defined as the time from
randomization to the first of two negative cultures at dif-
ferent visits without an intervening positive culture re-
sult, irrespective of whether there were subsequent
cultures positive for Mycobacterium tuberculosis, and
time to smear negative status defined analogously. Cul-
tures with contamination were excluded from all ana-
lyses and did not contribute to the definition of culture
negative status. TTP over time was analyzed using a
Bayesian non-linear mixed effects regression model as
described previously, [17] and was summarized as the
daily rate of change in log10(TTP) (bactericidal activity)
from day 0 to day 56, BA(0–56), where TTP is measured
in hours. The regression model implemented the specifi-
cation of normally distributed residuals and random co-
efficients. Bacterial killing is often observed to be greater
over the first 7–14 days of TB treatment [13]. However,
since the earliest cultures in the REMoxTB trial were at
7 and 14 days, it was not reasonable to consider the
early and late slopes separately and therefore BA(0–56)
was chosen as the most appropriate measure to reflect
the combination of both phases of killing. No culture re-
sults after treatment change or withdrawal from treat-
ment were included in the analysis. Cultures after week
8 were also not included in the modelling of TTP over
time to avoid undue influence in slope fitting of later
positive culture results in the small number of patients
that fail treatment and to more closely reflect a phase II
endpoint.
Baseline predictors of outcome were evaluated using
logistic regression separately within each treatment
group and also with all patients combined, adjusted for
treatment. Baseline covariates were evaluated firstly in
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univariable models and then in multivariable models if
significant (at the 5 % level) on the likelihood ratio test.
Baseline covariates tested were HIV status, presence of
cavities on chest X-ray, history of smoking, sex, race,
weight, body mass index (BMI), country and continent
of study centre, smear grade, solid culture (LJ) grade,
TTP on MGIT, CD4 count (HIV patients only) and re-
sistance to isoniazid.
Trial-level surrogacy was evaluated by plotting dif-
ferences between treatments on the marker of speed
of clearance of bacilli with 95 % confidence interval
against the differences on the primary endpoint. The
primary efficacy outcome was the proportion of patients
who had bacteriologically or clinically defined failure
or relapse within 18 months following randomization
(a composite unfavourable outcome). Negative culture
status at 18 months (at or after 72 weeks) was con-
sidered a favourable outcome provided there was no
prior unfavourable outcome and where the last posi-
tive culture result was followed by at least two nega-
tive culture results. The per protocol analysis
population was used for this analysis, as this approach
was closest to a pure bacteriological outcome of
failure/relapse. The between-treatment difference in
the probability of an unfavourable outcome was esti-
mated from a generalized linear model with identity-
link function adjusted for weight and study centre (as
was done in the primary trial analysis). Differences
between treatments with respect to time to culture or
smear negative status were characterized using a haz-
ard ratio from a Cox proportional hazards regression
model. Full details of the primary trial analyses are
given elsewhere [1].
Individual-level surrogacy was evaluated using the
non-parametric Cuzick test for trend [18] on categorical
variables and logistic regression to model the probability
of an unfavourable clinical outcome. The continuous
markers of speed of clearance of bacilli described above
were included as independent variables using fractional
polynomials [19] to allow for non-linear relationships.
Time of last culture was used for the few patients who
did not achieve culture or smear negative status (<5 %
on MGIT, <2 % on LJ, <2 % smear). An alternative ap-
proach of using multiple imputation with upper limit
censoring was used for the few patients that did not
achieve culture negative status, but results were un-
changed and so are not presented. The c-statistic [20],
calculated as the area under the receiver operating char-
acteristic curve (AUCROC), was used to compare predic-
tion models to identify the markers that had highest
discrimination between high risk and low risk patients.
Patients with missing values for the included baseline
covariates were excluded from the covariate-adjusted
AUCROC analysis.
Ethical review
The ethics committee at University College London
(London, UK) and all national and local ethics committees
approved the trial, including these analyses which were
planned as a secondary objective to the trial. All patients
provided written or witnessed oral informed consent.
Role of the funding source
The Global Alliance for TB Drug Development was
involved in study design, data interpretation and writing
of this report. All other funders were not involved in
study design, data interpretation or writing of the report.
The first author (PPJP) had full access to all the data in
the study and had final responsibility for the decision to
submit for publication.
Availability of data
Raw data from the REMoxTB trial is available for eligible
researchers as part of a repository of TB trial data. See
http://c-path.org/programs/tb-pacts/ for further details.
Results
Baseline predictors
After adjusting for treatment arm, HIV co-infection,
cavitation on X-ray, low BMI, history of smoking and
male gender (Table 1) were significant predictors of an
unfavourable outcome.
Trial-level surrogacy
Culture negative status on both LJ and MGIT, but not
smear negative status, was achieved earlier in both
moxifloxacin arms as compared to the control. For
time to culture negative status on MGIT the hazard
ratio was 1.16, 95 % CI (1.02, 1.30) for both arms
(log-rank p = 0.013 and p = 0.010 for the isoniazid and
ethambutol arms, respectively) and for time to culture
negative status on LJ the hazard ratio was 1.24, 95 % CI
(1.10, 1.40), p <0.001 for the isoniazid arm and 1.20, 95 %
CI (1.06, 1.35), p = 0.002 for the ethambutol arm. There
was no reduction in time to smear negative status, hazard
ratio 0.97, 95 % CI (0.86, 1.09), p = 0.503 for the isoniazid
arm and 0.96, 95 % CI (0.85, 1.08), p = 0.611 for the eth-
ambutol arm, compared to control. The daily rate of
change in log10(TTP) over time was bi-phasic with a tran-
sition point before 14 days (Fig. 1). The rate of change in
log10(TTP) from day 0 to day 56, BA(0–56), was
higher in the ethambutol arm (0.0139 log10(hours) per
day on treatment, 95 % Bayesian credibility interval
(BCI) 0.0130, 0.0142) than in the control arm (0.0128,
95 % BCI 0.0123, 0.0134), difference 0.0010 (95 %
BCI 0.0002, 0.0018). The rate of change in log10(TTP)
was not higher in the isoniazid arm (0.0136 95 % BCI
0.0133, 0.0145) than in the control arm, difference
0.0008 (95 % BCI −0.0001, 0.0016).
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Figure 2 shows the association between the difference
between treatments on the markers of speed of clearance
of bacilli and the difference between treatments on the
long-term clinical outcome for the three culture-based
markers. Each plotted point represents a single treat-
ment comparison.
Although there is a modest benefit in both moxifloxa-
cin arms with regard to each of the intermediate micro-
biological markers as compared to the control (the red
and green points lie above the horizontal line of no dif-
ference), there are more unfavourable clinical outcomes
(the red and green points lie to the right of the vertical
line of no difference). The treatment effects on the inter-
mediate and clinical outcomes are therefore in the op-
posite direction. Furthermore, although there is no
significant difference with regard to any of the inter-
mediate markers when comparing the two 4-month
moxifloxacin arms, there is a higher proportion of un-
favourable outcomes on the ethambutol arm. Similar re-
sults were seen for culture results at 6, 8 or 12 weeks
(graphs not shown). Thus, trial-level surrogacy is not
satisfied with any of these intermediate markers.
Individual-level surrogacy
Table 2 shows the number and proportion of patients
with an unfavourable outcome at the end of follow-up,
by categorical groupings of time to smear or culture
negative status on LJ or on MGIT, or quartiles of
BA(0–56). The proportion of patients with an unfavour-
able outcome is lower in those with faster clearance of ba-
cilli (earlier smear or culture negative status achieved or a
larger daily rate of change in log10(TTP)), p <0.001 in each
case for arms grouped together. Considered as continu-
ous, rather than categorical, all four intermediate markers
are independent predictors of an unfavourable outcome,
adjusted for treatment arm (Fig. 3, p <0.001). The curves
Table 1 Predictors of an unfavourable outcome for all data (adjusted for treatment) and within each treatment arm. Prediction
models fitted all factors significant in the “all data” model (p <0.05, likelihood ratio test) with the addition of TTP on MGIT which was
significant in the “ethambutol arm” model. Factors not listed in this table were not significant in any model
Multivariable odds ratio (95 % CI) All data Control arm patients only Isoniazid arm patients only Ethambutol arm patients only
Control Reference
Isoniazid 1.81 (1.18, 2.78)
Ethambutol 2.88 (1.92, 4.33)
p <0.001
BMI per 1 kg/m2 0.92 (0.87, 0.98) 0.93 (0.82, 1.05) 0.95 (0.85, 1.05) 0.90 (0.83, 0.99)
p = 0.004 p = 0.193 p = 0.286 p = 0.027
History of smoking 1.63 (1.15, 2.31) 2.12 (0.99, 4.53) 2.34 (1.23, 4.46) 1.15 (0.69, 1.92)
p = 0.005 p = 0.046 p = 0.007 p = 0.592
HIV positive 2.93 (1.69, 5.08) 2.64 (0.90, 7.78) 1.95 (0.72, 5.28) 4.46 (1.79, 11.09)
p <0.001 p = 0.100 p = 0.210 p = 0.002
TTP on MGIT (per 0.1 log10(day)) 0.97 (0.90, 1.05) 1.17 (1.03, 1.32)
a 1.02 (0.89, 1.17) 0.84 (0.74, 0.95)
p = 0.439 p = 0.024 p = 0.789 p = 0.003
Male gender 1.69 (1.13, 2.53) 1.10 (0.48, 2.55) 1.94 (0.94, 3.98) 2.09 (1.13, 3.85)
p = 0.009 p = 0.817 p = 0.060 p = 0.014
Cavities on X-ray 1.93 (1.22, 3.05) 1.62 (0.62, 4.19) 2.82 (1.15, 6.94) 1.75 (0.89, 3.41)
p = 0.003 p = 0.302 p = 0.013 p = 0.091
aThis association (p = 0.024) indicates a higher probability of an unfavourable outcome with higher TTP on MGIT, indicating a lower bacillary load which is
biologically counter-intuitive. This is a modest odds ratio with a fairly wide confidence interval—similar results are seen in the univariable model. Due to the multi-
plicity in the number of tests done to evaluate baseline predictors this is therefore likely a chance finding
Fig. 1 Fit of non-linear mixed effects model of MGIT TTP during the
first 56 days of treatment with three anti-tuberculosis regimens
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are distinct and approximately parallel showing that
the 6-month control regimen has better outcomes in-
dependently of speed of clearance of bacilli. However,
the probability of an unfavourable outcome is non-
zero for patients that achieve culture or smear nega-
tive status in the first few weeks as the curves reach
non-zero asymptotes.
While in a univariable model baseline TTP is a pre-
dictor of outcome, after adjusting for treatment arm and
intermediate marker, baseline TTP was not an independ-
ent predictor of outcome, p = 0.77 and p = 0.75 for time
to culture negative status on LJ and MGIT, respectively,
p = 0.09 for BA(0–56) and p = 0.68 for time to smear
negative status.
Comparing models
Table 3 shows the AUCROC for each of the markers
demonstrating the ability of the model to discriminate
unfavourable from favourable outcomes. Although the
confidence intervals around the estimates are fairly wide,
the estimates of AUC were higher for time to culture
negative status, BA(0–56) and time to smear than cul-
ture or smear results at a single visit indicating better
discrimination. Discrimination was improved on adjust-
ing for baseline covariates. However, none of the
markers resulted in greatly improved discrimination over
the reference model adjusted for baseline covariates with
the greatest improvements seen in the control arm.
Figure 4 shows ROC curves for a selection of markers.
Discussion
Our data show that while various measures of speed of
clearance of bacilli are predictors of clinical outcome,
the ability of each marker to actually discriminate be-
tween favourable and unfavourable status is poor. Time
to culture negative status on LJ and in MGIT, time to
smear negative status and the daily rate of change of
log10(TTP) in MGIT over 56 days tended to have higher
discrimination as predictors than a culture or smear
result at a single visit. Adjusting only for the baseline
covariates, with no on-treatment information, AUCs
ranged from 0.67 to 0.70 showing that each of these
intermediate markers only modestly improved the pre-
diction of an unfavourable outcome when important risk
factors are known, including HIV status, presence of
cavities, BMI and smoking history. In comparison, a
Fig. 2 Trial-level surrogacy plot. a Time to culture negative status on LJ. b Time to culture negative status in MGIT. c BA(0–56), daily rate of
change in log10(TTP) to day 56. The difference between treatments on the intermediate marker is plotted against the difference in unfavourable
outcome with 95 % confidence intervals. Points lying outside the yellow regions indicate that the treatment difference is in the opposite
direction on the intermediate marker from the long-term clinical outcome
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recent study in 35 patients assessed various positron
emission tomography/computed tomography (PET/CT)
imaging biomarkers with AUCROC upwards of 0.9, al-
though the authors acknowledge that this was a prelim-
inary, hypothesis-generating analysis with small patient
numbers [21].
An important finding in this work is that we demon-
strated that there is a small but non-negligible propor-
tion of patients who clear bacilli quickly but have a poor
long-term bacteriological outcome on all three arms.
This means that there are mechanisms of relapse that
are not captured by these culture-based intermediate
markers which only measure viable bacilli. This may be
because the sub-population of bacteria that go on to cause
relapse are lipid-rich, non-culturable persisters [6, 22, 23]
that undergo transcriptional adaptation [24] or are not ex-
pectorated in sputum [21].
We found that time to smear negative status was a
predictor of clinical outcome, although there was no dif-
ference in the effect of treatment on this endpoint indi-
cating that it is unsuitable as a primary endpoint for a
trial, in contrast to the faster time to culture negative
status seen in the moxifloxacin regimens. This is consist-
ent with the poor sensitivity of smear for predicting out-
come [7] and makes it unlikely to be a useful marker for
evaluating novel regimens.
The bi-phasic increase in log10(TTP) over time was
consistent with other studies and the estimate of the rate
of change in log10(TTP) of 0.013 in the control arm was
consistent with another recently published study where
the estimate was 0.017 [14].
TTP on MGIT at baseline, an established marker of
bacterial load, was not an independent predictor of out-
come after adjusting for these factors. Relapse rates have
Table 2 Number of patients with an unfavourable outcome by treatment arm and groupings of time to culture negative status on
LJ and MGIT. Groupings are quartiles or approximate quartiles for time to culture negative status
Time Control Isoniazid Ethambutol Total
Grouping n (%) / N n (%) / N n (%) / N n (%) / N n (%) / N
Time to culture negative status on LJa <4 weeks 8 (8 %) / 103 10 (9 %) / 106 14 (11 %) / 122 32 (10 %) / 331
4 to <6 weeks 7 (6 %) / 117 13 (9 %) / 139 19 (16 %) / 117 39 (10 %) / 373
6 to <8 weeks 6 (4 %) / 134 16 (12 %) / 132 33 (20 %) / 161 55 (13 %) / 427
8+ weeks 19 (12 %) / 153 37 (27 %) / 135 36 (30 %) / 121 92 (22 %) / 409
Total 40 (8 %) / 507 76 (15 %) / 512 102 (20 %) / 521 218 (14 %) / 1,540
Test for trend p = 0.275 p <0.001 p <0.001 p <0.001
Time to culture negative status in MGITb <6 weeks 4 (5 %) / 85 9 (8 %) / 109 12 (11 %) / 110 25 (8 %) / 304
6 to <8 weeks 4 (4 %) / 99 12 (10 %) / 116 15 (13 %) / 120 31 (9 %) / 335
8 to <12 weeks 3 (4 %) / 74 11 (14 %) / 76 14 (19 %) / 74 28 (13 %) / 224
12+ weeks 29 (12 %) / 249 43 (20 %) / 210 58 (27 %) / 214 130 (19 %) / 673
Total 40 (8 %) / 507 75 (15 %) / 511 99 (19 %) / 518 214 (14 %) / 1,536
Test for trend p = 0.013 p = 0.002 p <0.001 p <0.001
BA(0–56), daily rate of change in log10(TTP) to day 56
c <0.01153 17 (10 %) / 165 22 (19 %) / 116 30 (31 %) / 98 69 (18 %) / 379
0.01153 to <0.0137 11 (9 %) / 119 27 (21 %) / 130 30 (23 %) / 131 68 (18 %) / 380
0.0137 to <0.01581 7 (6 %) / 111 15 (11 %) / 133 24 (18 %) / 135 46 (12 %) / 379
>0.01581 4 (4 %) / 104 11 (9 %) / 127 20 (13 %) / 149 35 (9 %) / 380
Total 39 (8 %) / 499 75 (15 %) / 506 104 (20 %) / 513 218 (14 %) / 1,518
Test for trend p = 0.040 p = 0.004 p = 0.001 p <0.001
Time to smear negative statusd <4 weeks 11 (8 %) / 134 11 (7 %) / 154 21 (17 %) / 127 43 (10 %) / 415
4 to <6 weeks 10 (8 %) / 122 13 (13 %) / 101 17 (15 %) / 115 40 (12 %) / 338
6 to <8 weeks 4 (4 %) / 93 14 (17 %) / 82 15 (16 %) / 95 33 (12 %) / 270
8+ weeks 15 (9 %) / 158 37 (21 %) / 173 50 (27 %) / 185 102 (20 %) / 516
Total 40 (8 %) / 507 75 (15 %) / 510 103 (20 %) / 522 218 (14 %) / 1,539
Test for trend p = 0.926 p <0.001 p = 0.026 p <0.001
aExcluding 8 patients censored before time to culture negative status before 8 weeks; bexcluding 12 patients censored before time to culture negative status
before 12 weeks; cexcluding 30 patients with insufficient data to be included in model; dexcluding 9 patients censored before time to culture negative status
before 8 weeks. n, number of patients with an unfavourable outcome; N, number of assessable patients; %, number of patients with an unfavourable outcome
relative to the number of assessable patients
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been observed to differ between patients from Asia and
patients from Africa [16], but geographical region was
also not an independent predictor of outcome in this
study. These results indicate that patient factors and
cavitation are more important than bacillary load as risk
factors for a poor outcome of treatment.
In predicting the outcome for an individual patient,
delayed culture conversion is associated with an in-
creased risk of an unfavourable clinical outcome, but
discrimination is modest. Even on the ethambutol regi-
men which had the poorest results, the majority of pa-
tients who had not achieved culture negative status on
MGIT by 12 weeks (63 %) or who had not achieved cul-
ture negative status on LJ by 8 weeks (70 %) still went
on to have a favourable outcome. This shows the limita-
tions in using these markers in individual patient care.
There were some limitations in our study. We ex-
cluded results from contaminated cultures from all ana-
lyses, although these results might be informative for
prediction models. A thorough analysis of surrogate end-
points should include multiple treatment comparisons of
drugs with different mechanisms of action from multiple
trials. Unfortunately REMoxTB is the only TB phase III
trial of novel regimens to date with sufficiently frequent
cultures during treatment to allow an assessment of time
to culture conversion and daily rate of change of
log10(TTP) in MGIT to day 56 as putative surrogate
endpoints. As more trial data becomes available, these
analyses will be updated. In addition, we were unable to
definitively evaluate any of these markers as trial-level
surrogates due to the differences between regimens in
the continuation phase of treatment. This will be a fail-
ing of any putative surrogate endpoint that is measured
before the end of treatment, as it will not be able to fully
capture the treatment effect. However, the comparison
of the 4-month regimens showed that, even when the
duration of treatment is the same, while there was no
difference in speed of clearance of bacilli, there were
more unfavourable outcomes on the ethambutol arm.
This observation suggests two explanations. None of the
drugs being compared between regimens have tradition-
ally been thought to have strong sterilizing activity and
Fig. 3 Estimates of probability of an unfavourable outcome by treatment arm and by intermediate marker. a Time to culture negative status on
LJ. b Time to culture negative status in MGIT. c BA(0–56), daily rate of change in log10(TTP) to day 56. d Time to smear negative. Vertical solid and
dashed lines show various centiles of the intermediate markers for patients in the control arm in the REMoxTB trial
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Table 3 Table of area under the receiver operating characteristic curve (AUCROC) and 95 % confidence intervals for various models. Baseline covariates fitted in the adjusted
models include those found to be significant in Table 2: BMI, history of smoking, HIV status, gender, presence of cavitation and baseline DTP in MGIT
Control Isoniazid Ethambutol Combined (adjusted for treatment)
Unadjusted Adjusted for baseline
covariates
Unadjusted Adjusted for baseline
covariates
Unadjusted Adjusted for baseline
covariates
Unadjusted Adjusted for baseline
covariates
No on-treatment predictors (reference) 0.50 0.67 (0.57, 0.76) 0.50 0.70 (0.64, 0.77) 0.50 0.67 (0.61, 0.74) 0.60 (0.57, 0.64) 0.70 (0.66, 0.74)
BA(0–56), daily rate of change in
log10(TTP) to day 56
0.60 (0.52, 0.69) 0.73 (0.66, 0.81) 0.61 (0.55, 0.68) 0.72 (0.65, 0.79) 0.61 (0.55, 0.67) 0.70 (0.64, 0.76) 0.66 (0.62, 0.70) 0.73 (0.69, 0.76)
Time to culture negative status on LJ 0.61 (0.50, 0.72) 0.73 (0.63, 0.82) 0.67 (0.60, 0.74) 0.74 (0.67, 0.81) 0.63 (0.57, 0.69) 0.71 (0.65, 0.77) 0.70 (0.66, 0.74) 0.74 (0.70, 0.78)
Time to culture negative status in MGIT 0.59 (0.49, 0.70) 0.77 (0.69, 0.84) 0.62 (0.55, 0.69) 0.74 (0.67, 0.80) 0.64 (0.57, 0.70) 0.72 (0.66, 0.78) 0.67 (0.63, 0.70) 0.74 (0.70, 0.78)
Time to smear negative status 0.62 (0.51, 0.72) 0.72 (0.64, 0.79) 0.62 (0.56, 0.69) 0.73 (0.67, 0.79) 0.59 (0.53, 0.66) 0.68 (0.62, 0.74) 0.66 (0.62, 0.70) 0.72 (0.68, 0.76)
Week 6 culture on LJ 0.55 (0.47, 0.63) 0.68 (0.60, 0.75) 0.56 (0.50, 0.62) 0.70 (0.63, 0.77) 0.56 (0.51, 0.61) 0.68 (0.61, 0.74) 0.63 (0.59, 0.67) 0.71 (0.67, 0.75)
Week 8 culture on LJ 0.51 (0.45, 0.56) 0.66 (0.57, 0.74) 0.56 (0.51, 0.61) 0.71 (0.64, 0.77) 0.56 (0.52, 0.60) 0.69 (0.63, 0.75) 0.63 (0.59, 0.66) 0.71 (0.66, 0.75)
Week 12 culture on LJ 0.55 (0.50, 0.60) 0.71 (0.63, 0.80) 0.51 (0.49, 0.53) 0.69 (0.63, 0.76) 0.53 (0.50, 0.55) 0.69 (0.63, 0.75) 0.62 (0.59, 0.66) 0.71 (0.67, 0.75)
Week 6 culture in MGIT 0.49 (0.41, 0.57) 0.65 (0.55, 0.74) 0.51 (0.45, 0.57) 0.70 (0.63, 0.76) 0.54 (0.49, 0.60) 0.65 (0.59, 0.72) 0.61 (0.57, 0.64) 0.70 (0.66, 0.74)
Week 8 culture in MGIT 0.56 (0.48, 0.64) 0.70 (0.61, 0.79) 0.57 (0.51, 0.63) 0.71 (0.64, 0.78) 0.61 (0.55, 0.66) 0.70 (0.64, 0.76) 0.64 (0.60, 0.68) 0.72 (0.68, 0.76)
Week 12 culture in MGIT 0.58 (0.51, 0.65) 0.72 (0.64, 0.80) 0.54 (0.49, 0.58) 0.71 (0.64, 0.77) 0.55 (0.51, 0.59) 0.69 (0.63, 0.75) 0.63 (0.59, 0.67) 0.72 (0.68, 0.76)
Week 6 smear 0.49 (0.41, 0.57) 0.65 (0.56, 0.75) 0.53 (0.47, 0.59) 0.70 (0.63, 0.76) 0.57 (0.52, 0.63) 0.68 (0.62, 0.75) 0.62 (0.58, 0.66) 0.71 (0.67, 0.75)
Week 8 smear 0.53 (0.46, 0.61) 0.68 (0.59, 0.77) 0.55 (0.49, 0.61) 0.71 (0.64, 0.77) 0.57 (0.52, 0.62) 0.69 (0.63, 0.75) 0.63 (0.59, 0.67) 0.71 (0.67, 0.75)
Week 12 smear 0.54 (0.48, 0.61) 0.68 (0.60, 0.77) 0.55 (0.50, 0.60) 0.70 (0.64, 0.77) 0.58 (0.53, 0.62) 0.68 (0.62, 0.74) 0.63 (0.60, 0.67) 0.71 (0.67, 0.75)
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it may therefore be that trial-level surrogacy may be sat-
isfied in an evaluation of a regimen with a stronger ster-
ilizing effect such as one with an increased dose of
rifampicin. Nevertheless, a surrogate endpoint that is
dependent on the regimens under comparison will only
be of limited use in drug development decision-making.
Alternatively, these results may show that the addition
of isoniazid in the continuation phase of treatment does
help prevent relapse, which would support the important
role of isoniazid as a drug with both bactericidal and
sterilizing activity [25].
The primary endpoint of the REMoxTB trial was a
composite outcome including relapse and failure. The
majority of outcomes in the per protocol population
were confirmed by bacteriology, but a limitation of this
analysis is that a small number of outcomes may not
represent true treatment failures or relapses. Nevertheless,
this endpoint is the accepted endpoint for pivotal TB
phase III trials and is therefore most relevant for this sur-
rogacy analysis.
We welcome a recent model using the proportion of
patients that are culture positive at 2 months on LJ to
predict phase III outcomes [26], which performs fairly
well in a retrospective analysis using the results of inter-
mediate outcomes from the large phase III trials [27].
The prediction intervals are, however, wide (80 % inter-
vals are presented). The variability in the proportion
remaining culture positive after 2 months observed in
small phase II trials (20 % [28], 29 % [29] and 18 % [13]
for the ethambutol-sparing moxifloxacin regimen and 1 %
to 21 % [16] for the well-studied combination of daily
streptomycin, rifampicin, isoniazid and pyrazinamide)
means that the precision in predicting phase III trial re-
sults prospectively from phase II results is likely to be low.
Fig. 4 Receiver operating characteristic (ROC) curves. All curves represent models adjusted for baseline covariates. a Control arm. b Isoniaizid arm.
c Ethambutol arm
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The modest benefits with the addition of a fluoro-
quinolone seen in pre-clinical and early-phase clinical
trials did not enable treatment to be shortened from 6 to
4 months [30–32]. It is unclear how much larger the ef-
fects from novel regimens would need to be in order to
permit treatment-shortening, but we have shown that
markers that are better individual- and trial-level surro-
gates are also needed—preferably measured at the end
of treatment—to give greater confidence in moving
novel regimens to expensive phase III trials. Moreover,
the mechanism underlying the poor outcome in some
patients who cleared their infection rapidly from sputum
requires further investigation. Until improved markers
are available, culture-based markers will be the primary
endpoints in the middle phase of clinical development,
but results from these clinical trials should be inter-
preted with caution. Innovative clinical trial designs may
also have a role in managing the risk in moving between
phases of clinical trials [33, 34].
Conclusions
In summary, we have shown that culture conversion
during treatment for tuberculosis has only a limited role
in decision-making for advancing novel regimens into
pivotal phase III clinical trials or in predicting the out-
come of treatment for individual patients.
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